Effect of Combined Antihypertensive and Lipid-Lowering Therapies on Cognitive Function: A New Treatment Strategy?

被引:10
作者
Kuang, Ze-Min [1 ]
机构
[1] Capital Med Univ, Dept Hypertens, Beijing Anzhen Hosp, Beijing 100029, Peoples R China
关键词
CARDIOVASCULAR RISK-FACTORS; SYSTOLIC BLOOD-PRESSURE; SERUM-CHOLESTEROL; STATIN USE; ALZHEIMERS-DISEASE; DEMENTIA; DECLINE; ASSOCIATION; MIDLIFE; HYPERTENSION;
D O I
10.1155/2020/1484357
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Risk factors for cardiovascular disease such as hypertension and hyperlipidemia are associated with cognitive decline. However, there is still no clear evidence that the use of antihypertensive or lipid-lowering therapy can prevent or delay cognitive decline or development of dementia. To provide a reference for clinical treatment, we analyzed the potential mechanisms of cognitive dysfunction induced by hypertension and hyperlipidemia, the clinical research and controversy of antihypertensive and lipid-lowering therapies on cognitive function, and the clinical value of combined antihypertensive and lipid-lowering therapy. It is currently believed that hypertension and elevated blood cholesterol levels in middle-aged people may be related to cognitive impairment or dementia in the elderly. Some studies suggest that intensive antihypertensive or lipid-lowering therapies are better than standard antihypertensive or lipid-lowering therapy, yet further tests are needed to confirm their effects on cognitive function. Actively controlling potential risk factors from middle age may be important for Alzheimer's disease (AD) prevention.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
    Haywood, L. Julian
    Ford, Charles E.
    Crow, Richard S.
    Davis, Barry R.
    Massie, Barry M.
    Einhorn, Paula T.
    Williard, Angela
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (22) : 2023 - 2031
  • [42] Heart Failure With Preserved and Reduced Left Ventricular Ejection Fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    Davis, Barry R.
    Kostis, John B.
    Simpson, Lara M.
    Black, Henry R.
    Cushman, William C.
    Einhorn, Paula T.
    Farber, Michael A.
    Ford, Charles E.
    Levy, Daniel
    Massie, Barry M.
    Nawaz, Shah
    CIRCULATION, 2008, 118 (22) : 2259 - 2267
  • [43] Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    Alderman, Michael H.
    Piller, Linda B.
    Ford, Charles E.
    Probstfield, Jeffrey L.
    Oparil, Suzanne
    Cushman, William C.
    Einhorn, Paula T.
    Franklin, Stanley S.
    Papademetriou, Vasilios
    Ong, Stephen T.
    Eckfeldt, John H.
    Furberg, Curt D.
    Calhoun, David A.
    Davis, Barry R.
    HYPERTENSION, 2012, 59 (05) : 926 - +
  • [44] Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapyA cognitive study of patients enrolled in the FOURIER trial
    Giugliano, Robert P.
    Mach, Francois
    Zavitz, Kenton
    Kurtz, Christopher
    Schneider, Jingjing
    Wang, Huei
    Keech, Anthony
    Pedersen, Terje R.
    Sabatine, Marc S.
    Sever, Peter S.
    Honarpour, Narimon
    Wasserman, Scott M.
    Ott, Brian R.
    CLINICAL CARDIOLOGY, 2017, 40 (02) : 59 - 65
  • [45] Diuretic versus α-blocker as first-step antihypertensive therapy -: Final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Alderman, MH
    HYPERTENSION, 2003, 42 (03) : 239 - 246
  • [46] Associations of dyslipidaemia and lipid-lowering treatment with risk of postoperative cognitive dysfunction: a systematic review and meta-analysis
    Feinkohl, Insa
    Winterer, Georg
    Pischon, Tobias
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2018, 72 (06) : 499 - 506
  • [47] Lipid-Lowering Treatment and the Lipid Goals Attainment in Patients with a Very High Cardiovascular Risk
    Lis, Anna
    Lis, Paulina
    Lowicka, Weronika
    Grabarczyk, Malgorzata
    Wita, Michal
    Zarczynski, Piotr
    Zarczynska, Malgorzata
    Haberka, Maciej
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (08)
  • [48] Lack of a significant legacy effect of baseline blood pressure 'treatment naivety' on all-cause and cardiovascular mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    Ho, Chau L. B.
    Breslin, Monique
    Chowdhury, Enayet K.
    Doust, Jenny
    Reid, Christopher M.
    Davis, Barry R.
    Simpson, Lara M.
    Nelson, Mark R.
    JOURNAL OF HYPERTENSION, 2020, 38 (03) : 519 - 526
  • [49] Coronary Artery Calcium Measurement to Assist in Primary Prevention Decisions for Aspirin and Lipid-Lowering Therapies
    Osei, Albert D.
    Khan, Rozi
    Grandhi, Gowtham R.
    Boakye, Ellen
    Obisesan, Olufunmilayo H.
    Dzaye, Omar
    Blaha, Michael J.
    CURRENT CARDIOVASCULAR IMAGING REPORTS, 2021, 14 (11)
  • [50] Antihypertensive and lipid lowering treatment in stroke prevention current state and future
    Piechowski-Józwiak, B
    Bogousslavsky, J
    ACTA NEUROLOGICA BELGICA, 2005, 105 (02) : 57 - 61